Sensome announces initiation of clinical trial assessing its tissue micr...
PARIS, FRANCE - FEBRUARY 12TH, 2024 – Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD). Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.